# OnCo record zevorcabtagene-autoleucel (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/zevorcabtagene-autoleucel/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "zevorcabtagene-autoleucel" ;
  schema:name "Zevorcabtagene autoleucel"@en ;
  schema:description "Zevor-cel is CARsgen's myeloma CAR-T, approved in China in 2024 for patients whose disease has come back after three or more treatments."@en ;
  schema:url <https://onco.cc/drugs/zevorcabtagene-autoleucel/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.carsgen.com/en/>, <https://doi.org/10.1186/s40164-025-00710-y>, <https://doi.org/10.1007/s40291-024-00723-z> ;
  onco:status "approved" ;
  onco:tag "china" ;
  onco:modality "Cell therapy (autologous BCMA CAR-T, fully human binder)" ;
  schema:alternateName "Saikaize" ;
  onco:approval "China 2024: Relapsed or refractory multiple myeloma after three or more lines including a proteasome inhibitor and an immunomodulatory agent" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/> ;
  onco:technologies <https://onco.cc/technologies/car-t/> ;
  onco:targets <https://onco.cc/targets/bcma/> ;
  onco:companies <https://onco.cc/companies/carsgen/> ;
  onco:trials <https://onco.cc/trials/lummicar-1/>, <https://onco.cc/trials/nct03915184/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-chen-exp-hematol-oncol/>, <https://onco.cc/key-papers/paper-dhillon-mol-diagn-ther/> .